Colin Richard Green
Fondateur chez CoDa Therapeutics (NZ) Ltd.
Postes actifs de Colin Richard Green
Sociétés | Poste | Début | Fin |
---|---|---|---|
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Directeur/Membre du Conseil | 09/12/2003 | - |
Fondateur | 09/12/2003 | - | |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Fondateur | 01/01/2005 | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur Technique/Scientifique/R&D | - | - |
Fondateur | - | - |
Historique de carrière de Colin Richard Green
Anciens postes connus de Colin Richard Green
Sociétés | Poste | Début | Fin |
---|---|---|---|
AWE LIMITED | Directeur/Membre du Conseil | 17/03/1997 | 19/11/2009 |
Independent Dir/Board Member | 19/11/2009 | 19/11/2009 | |
Auckland University | Corporate Officer/Principal | - | - |
Formation de Colin Richard Green
Auckland University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Nouvelle-Zélande | 3 |
Australie | 2 |
Opérationnelle
Founder | 3 |
Director/Board Member | 2 |
Independent Dir/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Energy Minerals | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
AWE Pty Ltd.
AWE Pty Ltd. Oil & Gas ProductionEnergy Minerals AWE Pty Ltd. engages in the development and explored of oil and gas properties. Its projects includes Ande Ande Lumut Oil, BassGas, Casin Gas, Tui Area Oil, Lengo Gas, Waitsia Gas, Onshore Perth, Onshore Taranaki, and North Carnavon Basin. The company was founded by Bruce John Phillips on March 17, 1997 and is headquartered in North Sydney, Australia. | Energy Minerals |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Health Technology |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
- Bourse
- Insiders
- Colin Richard Green
- Expérience